Absorption Pharmaceuticals Expands Sales Force to Meet Extraordinary Demand for Promescent®
Enthusiasm among sexual dysfunction specialists for this breakthrough product in the treatment of male premature ejaculation is generating increasing demand from urologists, gynecologists and general practitioners.
Huntington Beach, CA (PRWEB) July 26, 2012
Absorption Pharmaceuticals, LLC today announced the hiring of four key sales executives to meet the growing demand for Promescent® – the most effective medical solution for treating male premature ejaculation (PE).
Jay Lovin, hired as the vice president of sales, brings more than 20 years of pharmaceutical sales and management experience, including his most recent role as regional sales director for Slate Pharmaceuticals, where he assembled and led the western U.S. sales organization and was instrumental in the successful launch of Slate’s testosterone replacement drug to the urological market. Prior to Slate, Jay was an award-winning district business manager for Wyeth/Pfizer.
Allan Kurz, hired as the national sales manager, served as the central regional sales director for Actient Pharmaceuticals where he led his sales team through the launch of a new buy and bill product, predominantly in the urology market. Allan has ten years of sales management experience in healthcare including a variety of roles with Wyeth and Pfizer Pharmaceuticals. He has contributed to the launch of numerous products to the physician and hospital markets.
Brady Smith, hired as the western regional sales manager, was an area sales manager for Slate Pharmaceuticals in the southwestern US. He brings over fifteen years of experience in both the pharmaceutical and bio-tech industries including numerous sales management positions with Wyeth Pharmaceuticals. Prior to Wyeth, Brady was the founder and CEO of a generic medication dispensing company that provides ancillary services for physician offices.
Frank Cortazzo, hired as the eastern regional sales manager, was an area sales manager in California and, prior to that, held several sales positions with Sunovion/Sepracor and Slate Pharmaceuticals. During his twelve years of pharmaceutical and biotech experience, Frank helped successfully launch numerous medications such as Lunesta®, Alvesco®, Omnaris®, Brovana®, and Xopenex® in a variety of markets across the U.S.
Jeff Abraham, Absorption Pharmaceutical´s CEO, commented, “We are excited to attract this top-flight talent to help make Promescent® the number one medical solution for PE. All of these experienced sales professionals have an extensive background in urological medications and are well-connected with medical practices nationwide that deal with men´s sexual health issues. Each member of this team had the opportunity to evaluate our unique product, its substantial market opportunity, and Absorption´s commitment to make Promescent® the clear choice for physicians treating PE. Their well-informed decision to enthusiastically join Absorption Pharmaceuticals is a strong endorsement of the substantial medical contribution and commercial success that we expect to achieve.”
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9737002.htm